IfPA’s Patient Access Policy Blog

Cardiovascular Group Rallies for Better Access Policies

Health plans across the country are rejecting prescriptions for cholesterol-lowering PCSK9 inhibitors at an average rate of 43 percent. And now one patient advocacy group

Read More

Massachusetts Pursues Better Access, Less Failure for Epilepsy Patients

In Massachusetts, some patients with epilepsy must try and fail on their health plans’ preferred prescription medications not once, not twice, but three times before

Read More

What’s Missing from Clinical Pathways in Cancer Care

Clinical pathways in the age of personalized cancer care may be excluding a key component: patient perspective.   In a Turning the Tide Against Cancer

Read More

Advocates Strategize on Pain Care Policy at GAfPA’s Malta Workshop

Young King David beat the biblical giant Goliath, as advocates at a Global Alliance for Patient Access workshop in Malta were recently reminded. In the

Read More

EU Group Calls for Greater Transparency in Labelling Biosimilars

EU regulators who want to encourage understanding and acceptance of biosimilar medicines might consider improving the drugs’ labels.  So says the stakeholders group EuropaBio, which

Read More

Research on Preventive Drugs Raises Hopes in the Migraine Community

For chronic migraine patients, the only thing better than making a headache stop is preventing it altogether.  And new research suggests that patients may soon

Read More

Patient Advocates Line Up Behind Federal Step Therapy Bill

A congressional effort to improve patients’ access to treatment is generating widespread enthusiasm in the advocacy community.  Sponsored by Rep. Brad Wenstrup, DPM, (R-Ohio) and

Read More

Cystic Fibrosis Group Defines Barriers to Treatment Access

Orphan drugs aren’t always reaching the patients who need them, and an advocacy group known as the Cystic Fibrosis Engagement Network has a few ideas

Read More

Drug Approval Signals New Era in Cancer Care

Is precision medicine gaining traction in the field of oncology?  The Food and Drug Administration’s recent approval of the cancer drug pembrolizumab offers a hint. 

Read More

High Out-of-Pocket Costs Threaten Access for Medicare Patients

Some Medicare beneficiaries pay 20 percent of their income in out-of-pocket medical expenses, a new study finds.  And a disproportionate number of those are low-income

Read More
Back to Top